Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMR in Untreated High-Risk Follicular Lymphoma
NCT00901927Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2009
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, mitoxantrone, rituximab in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2009; status: terminated.
02
Drugs
bendamustinemitoxantronerituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00901927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00901927.